AR and posterior cortical atrophy: CSCs enrichment has been associated to anticancer therapy resistance, and in PCa models several evidences suggest that CSCs contribute to resistance against chemotherapeutics, such as DTX or cabazitaxel, and androgen receptor inhibitors, such as enzalutamide [6, 57, 58].